Other languages ReShape Lifesciences Inc.

Equities

RSLS

US76090R2004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
0.1741 ^USD	+4.06%		+4.88%	-30.28%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Apr. 01	Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System	Mar. 28
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System	Mar. 28
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex	Feb. 22
Wall Street op nieuwe jaarrecords gesloten	Dec. 13
Top Midday Gainers	Dec. 13
Wall Street in afwachting van rentebesluit	Dec. 13
Licht hogere start voor Wall Street	Dec. 13
ReShape Lifesciences®? Receives FDA PMA Supplement Approval for Its Next-Generation Lap-Band®? 2.0 FLEX	Dec. 12
ReShape Lifesciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Sector Update: Health Care Stocks Lower Late Afternoon	23-09-29
Sector Update: Health Care Stocks Declining Friday Afternoon	23-09-29
ReShape Lifesciences Prices $3 Million Offering at $0.33 Per Unit	23-09-29
ReShape Lifesciences Inc. Signs Exclusive License Agreement With Biorad Medisys for Obalon(R) Gastric Balloon System	23-09-21
ReShape Lifesciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
Reshape Lifesciences Inc. Signs Preferred Partner Agreement with Hive Medical for Lead Optimization Software	23-06-29
ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting	23-06-28
ReShape Lifesciences Files US FDA Premarket Approval Supplement Application for Lap-Band 2.0; Shares Surge After Hours	23-06-26
ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-BandÂ® 2.0	23-06-26
ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ReShape Lifesciences Inc.

Equities

RSLS

US76090R2004

Other languages

Filters